The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

GHRP-6

Research chemical · Grade C

Goals
muscle, gut
Evidence
—
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
Results: distribution half-life (t½α) = 7.6 ± 1.9 minutes
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

AOD-9604

Research chemical · Grade C

Goals
weight-loss, muscle, hormonal
Evidence
6 RCT / 4 animal / 3 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Cagrilintide

Research chemical · Grade C

Goals
weight-loss, gut
Evidence
3 RCT / 1 animal / 0 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

CIT Stack

Research chemical · Grade C

Goals
muscle, sleep, weight-loss
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
The CIT Blend uses CJC-1295 WITHOUT DAC (also called Mod GRF 1-29) — the pulsatile form with ~30 min half-life
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →